États-Unis · Plateformes & données · TipRanks

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

Publié par TipRanks · États-Unis il y a 11 h

Pfizer (PFE) announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, ...

Lire l'article complet sur TipRanks Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.tipranks.com)

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

À lire aussi

Vanguard S&P 500 ETF Long-Term Outlook: What Historical Trends Suggest for Patient Investors

Oppenheimer reiterates Amgen stock rating on cancer drug data

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Roche lung cancer drug extends survival by nearly six months in late-stage trial

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

Partager

À lire aussi

Vanguard S&P 500 ETF Long-Term Outlook: What Historical Trends Suggest for Patient Investors

Oppenheimer reiterates Amgen stock rating on cancer drug data

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Roche lung cancer drug extends survival by nearly six months in late-stage trial

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120